BioLineRx Announces Collaboration with MSD to investigate the combination of KEYTRUDA® (pembrolizumab) and BL-8040 in Pancreatic Cancer

BioLineRx Ltd. (NASDAQ/TASE: BLRX) today announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx’s BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer.